{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:40:30Z","timestamp":1794915630272,"version":"4.9.1"},"reference-count":85,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":266,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0108673"],"award-info":[{"award-number":["JP24fk0108673"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24gm1610013"],"award-info":[{"award-number":["JP24gm1610013"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24jm0210111"],"award-info":[{"award-number":["24jm0210111"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0108673"],"award-info":[{"award-number":["JP24fk0108673"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24gm1610013"],"award-info":[{"award-number":["JP24gm1610013"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24jm0210111"],"award-info":[{"award-number":["24jm0210111"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The management of Mycobacterium avium complex pulmonary disease (MAC-PD) is challenging because of limited efficacy and frequent adverse events associated with standard treatments. The 2020 guidelines from the American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, and Infectious Diseases Society of America provide recommendations, but real-world adherence is often hindered by these issues, leading many patients to be unable to complete standard therapy. This review proposes a comprehensive management algorithm for MAC-PD, emphasizing multidisciplinary approaches and integrating nonantimicrobial management before, during, and after drug treatment to enhance patient outcomes. When a patient presents with chronic respiratory symptoms suggestive of nontuberculous mycobacteria, clinicians should follow a guideline-based approach to diagnosis, as diagnostic delays are common because of nonspecific symptoms. Proper evaluation should determine the disease phenotype (existence of cavitary lesions), as it influences treatment choices. Airway clearance, nutritional support, and management of underlying conditions are essential nonantimicrobial components. Regular outpatient monitoring helps detect disease progression and optimize treatment. Treatment strategies vary based on disease severity. For noncavitary nodular bronchiectatic disease, a thrice-weekly regimen is preferred because of better tolerability. Severe cases or those with cavitary forms may require daily treatment with additional aminoglycosides. Amikacin liposome inhalation suspension is recommended for patients not responding to standard regimens after 6 months. Recent research addresses drug intolerance, suggesting alternatives such as a two-drug regimen without rifamycin in certain cases. Consultation with nontuberculous mycobacteria specialists is advised for complex cases, particularly those with macrolide resistance or requiring surgical intervention. The algorithm emphasizes shared decision making, patient education, and family support to improve adherence and outcomes.<\/jats:p>","DOI":"10.1513\/annalsats.202408-904fr","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T16:55:06Z","timestamp":1739292906000},"page":"651-659","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":8,"title":["Comprehensive Management Algorithm for\n                    <i>Mycobacterium avium<\/i>\n                    Complex Pulmonary Disease in the Real-World Setting"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8239-9275","authenticated-orcid":false,"given":"Kozo","family":"Morimoto","sequence":"first","affiliation":[{"name":"Respiratory Disease Center and"},{"name":"Division of Clinical Research, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan"},{"name":"Department of Clinical Mycobacteriosis, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3324-926X","authenticated-orcid":false,"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[{"name":"Department of Medicine, National Jewish Health, Denver, Colorado; and"},{"name":"Department of Medicine, University of Colorado, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"2026012203063141300_bib1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ccm.2023.08.012","article-title":"Global epidemiology of nontuberculous mycobacterial pulmonary disease: a review","volume":"44","author":"Prevots","year":"2023","journal-title":"Clin Chest Med"},{"key":"2026012203063141300_bib2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","article-title":"Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review","volume":"125","author":"Dahl","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026012203063141300_bib3","doi-asserted-by":"crossref","first-page":"1601855","DOI":"10.1183\/13993003.01855-2016","article-title":"Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases","volume":"49","author":"van Ingen","year":"2017","journal-title":"Eur Respir J"},{"key":"2026012203063141300_bib4","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"2026012203063141300_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.rmed.2019.10.002","article-title":"Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in Japan","volume":"158","author":"Morimoto","year":"2019","journal-title":"Respir Med"},{"key":"2026012203063141300_bib6","doi-asserted-by":"crossref","first-page":"00097-2019","DOI":"10.1183\/23120541.00097-2019","article-title":"Population-based survey of antimycobacterial drug use among patients with non-tuberculosis mycobacterial pulmonary disease","volume":"6","author":"Izumi","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026012203063141300_bib7","doi-asserted-by":"crossref","first-page":"e1408","DOI":"10.1093\/cid\/ciac394","article-title":"Evaluation of Mycobacterium avium complex pulmonary disease treatment completion and adherence to ATS\/IDSA guidelines","volume":"76","author":"Ku","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026012203063141300_bib8","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3390\/antibiotics11121720","article-title":"Epidemiology, outcomes and tolerability of protracted treatment of nontuberculous mycobacterial infections at a community teaching hospital in the southeastern United States","volume":"11","author":"Tsai","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2026012203063141300_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.resinv.2022.05.006","article-title":"Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease","volume":"60","author":"Ito","year":"2022","journal-title":"Respir Investig"},{"key":"2026012203063141300_bib10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/17476348.2021.1887734","article-title":"A multidisciplinary approach to the management of nontuberculous mycobacterial lung disease: a clinical perspective","volume":"15","author":"Ali","year":"2021","journal-title":"Expert Rev Respir Med"},{"key":"2026012203063141300_bib11","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.21037\/jtd-22-410","article-title":"Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review","volume":"14","author":"Youssefnia","year":"2022","journal-title":"J Thorac Dis"},{"key":"2026012203063141300_bib12","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jfma.2020.05.013","article-title":"Nonpharmacological treatment for patients with nontuberculous mycobacterial lung disease","volume":"119","author":"Lan","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"2026012203063141300_bib13","doi-asserted-by":"crossref","first-page":"00574-2020","DOI":"10.1183\/23120541.00574-2020","article-title":"Nontuberculous mycobacterial pulmonary disease: an integrated approach beyond antibiotics","volume":"7","author":"Faverio","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026012203063141300_bib14","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s10096-015-2432-8","article-title":"Clinical findings in relation to mortality in non-tuberculous mycobacterial infections: patients with Mycobacterium avium complex have better survival than patients with other mycobacteria","volume":"34","author":"Kotilainen","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026012203063141300_bib15","doi-asserted-by":"crossref","first-page":"00737-2022","DOI":"10.1183\/23120541.00737-2022","article-title":"Global survey of physician testing practices for nontuberculous mycobacteria","volume":"9","author":"Loebinger","year":"2023","journal-title":"ERJ Open Res"},{"key":"2026012203063141300_bib16","doi-asserted-by":"crossref","first-page":"107627","DOI":"10.1016\/j.rmed.2024.107627","article-title":"Beyond symptoms: radiologic identification of asymptomatic Mycobacterium avium complex pulmonary infections","volume":"226","author":"Fujiwara","year":"2024","journal-title":"Respir Med"},{"key":"2026012203063141300_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.rmed.2019.02.007","article-title":"The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"150","author":"Kwon","year":"2019","journal-title":"Respir Med"},{"key":"2026012203063141300_bib18","doi-asserted-by":"crossref","first-page":"1600537","DOI":"10.1183\/13993003.00537-2016","article-title":"Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course","volume":"49","author":"Hwang","year":"2017","journal-title":"Eur Respir J"},{"key":"2026012203063141300_bib19","doi-asserted-by":"crossref","first-page":"e008058","DOI":"10.1136\/bmjopen-2015-008058","article-title":"Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular\/bronchiectatic Mycobacterium avium complex lung disease","volume":"5","author":"Gochi","year":"2015","journal-title":"BMJ Open"},{"key":"2026012203063141300_bib20","doi-asserted-by":"crossref","first-page":"1602503","DOI":"10.1183\/13993003.02503-2016","article-title":"Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype","volume":"50","author":"Koh","year":"2017","journal-title":"Eur Respir J"},{"key":"2026012203063141300_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12931-020-1273-x","article-title":"Characteristic chest CT findings for progressive cavities in Mycobacterium avium complex pulmonary disease: a retrospective cohort study","volume":"21","author":"Oshitani","year":"2020","journal-title":"Respir Res"},{"key":"2026012203063141300_bib22","doi-asserted-by":"crossref","first-page":"ofab087","DOI":"10.1093\/ofid\/ofab087","article-title":"Clinical implications of size of cavities in patients with nontuberculous mycobacterial pulmonary disease: a single-center cohort study","volume":"8","author":"Kang","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026012203063141300_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.resinv.2021.09.011","article-title":"Influence of chronic sputum symptoms on quality of life in patients with nontuberculous mycobacterial pulmonary disease: a cross-sectional study","volume":"60","author":"Yamane","year":"2022","journal-title":"Respir Investig"},{"key":"2026012203063141300_bib24","doi-asserted-by":"crossref","first-page":"e000050","DOI":"10.1136\/bmjresp-2014-000050","article-title":"Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease","volume":"1","author":"Fujita","year":"2014","journal-title":"BMJ Open Respir Res"},{"key":"2026012203063141300_bib25","doi-asserted-by":"crossref","first-page":"107417","DOI":"10.1016\/j.rmed.2023.107417","article-title":"Multiple bacterial culture positivity reflects the severity and prognosis as bronchiectasis in Mycobacterium avium complex pulmonary disease","volume":"219","author":"Ito","year":"2023","journal-title":"Respir Med"},{"key":"2026012203063141300_bib26","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.chest.2020.06.050","article-title":"Airway clearance techniques in bronchiectasis: analysis from the United States Bronchiectasis and Non-TB Mycobacteria Research Registry","volume":"158","author":"Basavaraj","year":"2020","journal-title":"Chest"},{"key":"2026012203063141300_bib27","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/cid\/cix479","article-title":"Microbiological persistence in patients with Mycobacterium avium complex lung disease: the predictors and the impact on radiographic progression","volume":"65","author":"Pan","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026012203063141300_bib28","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3201\/eid2808.212375","article-title":"Incidence of nontuberculous mycobacterial pulmonary infection, by ethnic group, Hawaii, USA, 2005-2019","volume":"28","author":"Blakney","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2026012203063141300_bib29","doi-asserted-by":"crossref","first-page":"17180","DOI":"10.1038\/s41598-022-21511-x","article-title":"Severity of underweight affects the development of nontuberculous mycobacterial pulmonary disease; a nationwide longitudinal study","volume":"12","author":"Kang","year":"2022","journal-title":"Sci Rep"},{"key":"2026012203063141300_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jinf.2019.07.014","article-title":"Body composition changes successfully classify prognosis in patients with mycobacterium avium complex lung disease","volume":"79","author":"Akahori","year":"2019","journal-title":"J Infect"},{"key":"2026012203063141300_bib31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12890-020-01304-6","article-title":"Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis","volume":"20","author":"Uno","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2026012203063141300_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1378\/chest.10-0186","article-title":"Nontuberculous mycobacterial infection as a cause of difficult-to-control asthma: a case-control study","volume":"139","author":"Fritscher","year":"2011","journal-title":"Chest"},{"key":"2026012203063141300_bib33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5588\/ijtld.11.0412","article-title":"Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease","volume":"16","author":"Huang","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012203063141300_bib34","doi-asserted-by":"crossref","first-page":"e0230746","DOI":"10.1371\/journal.pone.0230746","article-title":"Incidence and etiology of chronic pulmonary infections in patients with idiopathic pulmonary fibrosis","volume":"15","author":"Odashima","year":"2020","journal-title":"PLoS One"},{"key":"2026012203063141300_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12890-022-01991-3","article-title":"Osteoporosis in nontuberculous mycobacterial pulmonary disease: a cross-sectional study","volume":"22","author":"Tanaka","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026012203063141300_bib36","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3201\/eid2108.141846","article-title":"Risk for mycobacterial disease among patients with rheumatoid arthritis, Taiwan, 2001-2011","volume":"21","author":"Liao","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2026012203063141300_bib37","doi-asserted-by":"crossref","first-page":"e0451122","DOI":"10.1128\/spectrum.04511-22","article-title":"Type 2 diabetes mellitus- and complication-related risk of nontuberculous mycobacterial disease in a South Korean Cohort","volume":"11","author":"Jeon","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026012203063141300_bib38","doi-asserted-by":"crossref","first-page":"1900798","DOI":"10.1183\/13993003.00798-2019","article-title":"Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study","volume":"55","author":"Jhun","year":"2020","journal-title":"Eur Respir J"},{"key":"2026012203063141300_bib39","doi-asserted-by":"crossref","first-page":"105955","DOI":"10.1016\/j.rmed.2020.105955","article-title":"Impact of Aspergillus precipitating antibody test results on clinical outcomes of patients with Mycobacterium avium complex lung disease","volume":"166","author":"Shirai","year":"2020","journal-title":"Respir Med"},{"key":"2026012203063141300_bib40","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1513\/AnnalsATS.202201-002VP","article-title":"Treatment of nontuberculous mycobacterial lung disease is complex; thus, shared decision making is critical","volume":"19","author":"Marmor","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203063141300_bib41","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.chest.2021.10.048","article-title":"Impact of time between diagnosis and treatment for nontuberculous mycobacterial pulmonary disease on culture conversion and all-cause mortality","volume":"161","author":"Im","year":"2022","journal-title":"Chest"},{"key":"2026012203063141300_bib42","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.chest.2023.06.015","article-title":"Microbiological cure at treatment completion is associated with longer survival in patients with Mycobacterium avium complex pulmonary disease","volume":"164","author":"Kim","year":"2023","journal-title":"Chest"},{"key":"2026012203063141300_bib43","doi-asserted-by":"crossref","first-page":"106340","DOI":"10.1016\/j.rmed.2021.106340","article-title":"Cavity formation and its predictors in noncavitary nodular bronchiectatic Mycobacterium avium complex pulmonary disease","volume":"179","author":"Han","year":"2021","journal-title":"Respir Med"},{"key":"2026012203063141300_bib44","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1038\/s41598-023-34576-z","article-title":"The factors associated with mortality and progressive disease of nontuberculous mycobacterial lung disease: a systematic review and meta-analysis","volume":"13","author":"Hwang","year":"2023","journal-title":"Sci Rep"},{"key":"2026012203063141300_bib45","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s40121-024-01015-z","article-title":"Real-world patients\u2019 diagnosis-to-treatment journey with nontuberculous mycobacterial pulmonary disease: a cross-sectional survey","volume":"13","author":"Morimoto","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026012203063141300_bib46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s12890-022-02109-5","article-title":"Nutritional status in female patients with nontuberculous mycobacterial lung disease and its association with disease severity","volume":"22","author":"Takayama","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2026012203063141300_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1513\/AnnalsATS.201812-915OC","article-title":"Association between Mycobacterium avium complex pulmonary disease and mycobacteria in home water and soil","volume":"17","author":"Tzou","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203063141300_bib48","first-page":"27","article-title":"Infection sources of a common non-tuberculous mycobacterial pathogen, Mycobacterium avium complex","volume":"4","author":"Nishiuchi","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"2026012203063141300_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccm.2014.10.003","article-title":"Environmental sources of nontuberculous mycobacteria","volume":"36","author":"Falkinham","year":"2015","journal-title":"Clin Chest Med"},{"key":"2026012203063141300_bib50","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.10-2315","article-title":"Environmental risk factors for pulmonary Mycobacterium avium-intracellulare complex disease","volume":"140","author":"Maekawa","year":"2011","journal-title":"Chest"},{"key":"2026012203063141300_bib51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jgar.2020.01.004","article-title":"Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: a propensity score analysis","volume":"22","author":"Kwon","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2026012203063141300_bib52","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.resinv.2020.09.010","article-title":"Resumption\/efficacy and safety of an azithromycin-containing regimen against Mycobacterium avium complex lung disease in patients who experienced adverse effects with a clarithromycin-containing regimen","volume":"59","author":"Kobayashi","year":"2021","journal-title":"Respir Investig"},{"key":"2026012203063141300_bib53","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203063141300_bib54","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1513\/AnnalsATS.202008-925OC","article-title":"Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: a 12-month open-label extension clinical trial","volume":"18","author":"Winthrop","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203063141300_bib55","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2021.03.070","article-title":"Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure","volume":"160","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"2026012203063141300_bib56","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s41030-024-00263-1","article-title":"Qualitative interviews exploring adverse event mitigation strategies in adults receiving amikacin liposome inhalation suspension","volume":"10","author":"Ali","year":"2024","journal-title":"Pulm Ther"},{"key":"2026012203063141300_bib57","doi-asserted-by":"crossref","first-page":"872","DOI":"10.5588\/ijtld.23.0275","article-title":"Management of dysphonia caused by amikacin liposome inhalation in M. avium complex pulmonary disease","volume":"27","author":"Kurahara","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012203063141300_bib58","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/azalide therapy for nodular\/bronchiectatic mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"key":"2026012203063141300_bib59","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.201408-1545OC","article-title":"Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"191","author":"Jeong","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203063141300_bib60","doi-asserted-by":"crossref","first-page":"e000434","DOI":"10.1136\/bmjresp-2019-000434","article-title":"Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular\/bronchiectatic Mycobacterium avium complex lung disease with rifampicin, ethambutol and clarithromycin (iREC): study protocol","volume":"6","author":"Nakagawa","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"2026012203063141300_bib61","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/rccm.200509-1531OC","article-title":"Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease","volume":"173","author":"Lam","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203063141300_bib62","doi-asserted-by":"crossref","first-page":"e0100323","DOI":"10.1128\/aac.01003-23","article-title":"Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type Mycobacterium avium complex pulmonary disease in relation to sputum smear results: a retrospective cohort study","volume":"67","author":"Jung","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203063141300_bib63","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1093\/cid\/ciaa1361","article-title":"Management of drug toxicity in Mycobacterium avium complex pulmonary disease: an expert panel survey","volume":"73","author":"van Ingen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026012203063141300_bib64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease: a preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203063141300_bib65","doi-asserted-by":"crossref","first-page":"106025","DOI":"10.1016\/j.rmed.2020.106025","article-title":"Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy","volume":"169","author":"Ito","year":"2020","journal-title":"Respir Med"},{"key":"2026012203063141300_bib66","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s12879-022-07568-z","article-title":"Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system","volume":"22","author":"Ozawa","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026012203063141300_bib67","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.5588\/ijtld.18.0171","article-title":"Adverse reactions associated with long-term drug administration in Mycobacterium avium complex lung disease","volume":"22","author":"Kamii","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012203063141300_bib68","first-page":"879","article-title":"Low-dosage ethambutol, less than 12.5 mg\/kg\/day, does not worsen the clinical outcomes of pulmonary Mycobacterium avium and Mycobacterium intracellulare disease: a retrospective cohort study","volume":"50","author":"Watanabe","year":"2022","journal-title":"Infection"},{"key":"2026012203063141300_bib69","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.resinv.2021.06.010","article-title":"Lower dose of ethambutol may reduce ocular toxicity without radiological deterioration for Mycobacterium avium complex pulmonary disease","volume":"59","author":"Ando","year":"2021","journal-title":"Respir Investig"},{"key":"2026012203063141300_bib70","doi-asserted-by":"crossref","first-page":"452","DOI":"10.5588\/ijtld.16.0711","article-title":"Clinical significance of the radiological severity score in Mycobacterium avium complex lung disease patients","volume":"21","author":"Furuuchi","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026012203063141300_bib71","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.chest.2019.12.016","article-title":"Treatment duration and disease recurrence following the successful treatment of patients with Mycobacterium avium complex lung disease","volume":"157","author":"Furuuchi","year":"2020","journal-title":"Chest"},{"key":"2026012203063141300_bib72","doi-asserted-by":"crossref","first-page":"e0474122","DOI":"10.1128\/spectrum.04741-22","article-title":"Comparison of treatment outcomes of cavitary Mycobacterium avium complex pulmonary disease with streptomycin or amikacin use","volume":"11","author":"Kim","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026012203063141300_bib73","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1128\/AAC.00648-15","article-title":"Response to switch from intermittent therapy to daily therapy for refractory nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"59","author":"Koh","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203063141300_bib74","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203063141300_bib75","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203063141300_bib76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12879-016-1384-7","article-title":"Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease","volume":"16","author":"Kadota","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2026012203063141300_bib77","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026012203063141300_bib78","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.chest.2022.09.037","article-title":"Outcomes of adjunctive surgery in patients with nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis","volume":"163","author":"Kim","year":"2023","journal-title":"Chest"},{"key":"2026012203063141300_bib79","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jiac.2018.04.002","article-title":"Risk stratification for the development of chronic pulmonary aspergillosis in patients with Mycobacterium avium complex lung disease","volume":"24","author":"Furuuchi","year":"2018","journal-title":"J Infect Chemother"},{"key":"2026012203063141300_bib80","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"key":"2026012203063141300_bib81","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/cid\/ciad108","article-title":"Impact of treatment on long-term survival of patients with Mycobacterium avium complex pulmonary disease","volume":"77","author":"Kim","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026012203063141300_bib82","doi-asserted-by":"crossref","first-page":"868435","DOI":"10.3389\/fmicb.2022.868435","article-title":"Impacts of nontuberculous mycobacteria isolates in non-cystic fibrosis bronchiectasis: a 16-year cohort study in Taiwan","volume":"13","author":"Lin","year":"2022","journal-title":"Front Microbiol"},{"key":"2026012203063141300_bib83","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"key":"2026012203063141300_bib84","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jiac.2017.12.008","article-title":"The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: a retrospective case-series study","volume":"24","author":"Hosono","year":"2018","journal-title":"J Infect Chemother"},{"key":"2026012203063141300_bib85","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijantimicag.2014.03.017","article-title":"Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: a propensity score analysis","volume":"44","author":"Komiya","year":"2014","journal-title":"Int J Antimicrob Agents"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/5\/651\/66015511\/annalsats_22_5_651.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/5\/651\/66015511\/annalsats_22_5_651.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:07:00Z","timestamp":1769069220000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/22\/5\/651\/8380534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":85,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,1]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202408-904fr","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"2024-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}